Beyond unfractionated heparin and warfarin: current and future advances.
Henderson Research Centre, Hamilton Health Sciences Corporatin, Ontario, Canada.
Jack
J
Hirsh
Martin
M
O'Donnell
John W
JW
Eikelboom
D000789:Angina, Unstable / Q000188:drug therapy; D000925:Anticoagulants / Q000009:adverse effects / Q000145:classification / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001384:Azetidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D001596:Benzylamines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003374:Coumarins / Q000627:therapeutic use; D000069604:Dabigatran; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000145:classification / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077425:Fondaparinux; D005544:Forecasting; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006629:Hirudins / Q000493:pharmacokinetics; D006801:Humans; D009025:Morpholines / Q000493:pharmacokinetics / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy; D010446:Peptide Fragments / Q000493:pharmacokinetics / Q000627:therapeutic use; D011134:Polysaccharides / Q000494:pharmacology / Q000627:therapeutic use; D011516:Prothrombin / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069552:Rivaroxaban; D013876:Thiophenes / Q000493:pharmacokinetics / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors; D019851:Thrombophilia / Q000188:drug therapy*; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D001384:Azetidines; D001562:Benzimidazoles; D001596:Benzylamines; D003374:Coumarins; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006629:Hirudins; D009025:Morpholines; D010446:Peptide Fragments; D011134:Polysaccharides; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D011994:Recombinant Proteins; D013876:Thiophenes; C522181:apixaban; C426686:ximelagatran; D014859:Warfarin; D011516:Prothrombin; C025337:Factor IIa; D006493:Heparin; D000069552:Rivaroxaban; D013917:Thrombin; D000069604:Dabigatran; D000077425:Fondaparinux; C074619:bivalirudin